arrow
A

Alessandro Cavaliere

university of verona
H指数:13
被引数:529

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A Comparative Study of Methyl-BEAMing and Droplet Digital PCR for MGMT Gene Promoter Hypermethylation Detection

甲基BEAMing和液滴数字PCR检测MGMT基因启动子甲基化的比较研究

2024-11-050
OA
Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv)

具有种系BRCA1-2致病变异 (gBRCA1-2pv) 的胰腺导管腺癌 (PDAC) 患者的二线治疗

2022-12-085
OA
Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey
2021-10-0117
OAAI
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort
2021-02-0126
OAAI
KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities

KRAS野生型胰腺导管腺癌: 分子病理学和治疗机会

2020-10-2861
OAAI
A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial
2020-09-0410
OAAI
Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer

血浆IL8是TAK1激活的生物标志物,可预测吉西他滨难治性胰腺癌患者对纳米脂质体伊立替康的耐药性

2020-09-0122
OAAI
Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemic
2020-08-0119
OAAI
A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal-gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial
2020-07-0729
OAAI